Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...

Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriasis taking methotrexate were 2.8 times more likely to develop nonmelanoma skin cancer than ...

Methotrexate The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported. More patients with psoriasis who were treated with subcutaneous ...

Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment. Patients with psoriasis who are treated with ...

An article published in the International Journal of Dermatology evaluated the drug survival of methotrexate in patients with psoriasis. This single-center retrospective study assessed the clinical ...

A close-up of bad psoriasis on a person’s arm An international consensus establishes methotrexate dosing recommendations for psoriasis treatment and identifies current knowledge gaps on the topic. A ...

A new study published in Dermatology just put to rest the idea that biologics or methotrexate might double as anti-diabetes ...

When you have psoriasis, your immune system sends out signals that cause your skin cells to renew themselves too fast. This too-active immune response is what makes scales and red patches form on your ...

This transcript has been edited for clarity. Stanley Cohen, MD: I am Dr Stanley Cohen and welcome to Medscape's InDiscussion series on psoriatic arthritis. This is episode 3 of the second season.

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with adalimumab alone, according to a UK cohort study of patients with plaque ...